Document:

EX-10.36

 Exhibit 10.36 
 SIGN AND RETURN THIS PAGE TO CIRM DR2A-05416 
 NOTICE OF LOAN AWARD – CIRM
RFA 10-05: Disease Team Therapy Development 
 Research Awards 

California Institute for Regenerative Medicine 
 Issue Date: April 9th, 2013 

							
	 Loan Number:
 Loan
Recipient Name:
	 	 DR2A-05416

StemCells, Inc.
	 	Budget Period:	  	On or before 1/1/2014
	Organization ID:	 	PR-Y0027A-LA	 	Project Period Start:	  	On or before 1/1/2014
	 Principal Investigator:

Co-Principal Investigator (s):
	 	 Alexandra Capela

Frank LaFerla
	 	Project Period End:	  	 6/30/2017 (assuming a

7/1/2013 Project Start Date)

	Project Title:	 	Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy

  

			
	Authorized Organizational Official and Address:	  	Official and Address to Receive Payments:
	 Ann Tsukamoto, Executive VP, Res & Dev
 7707 Gateway Blvd.
 Newark, CA 94560
	  	 Rodney Young, Chief Financial Officer
 7707 Gateway Blvd.
 Newark, CA 94560

 The California Institute for Regenerative Medicine hereby awards a loan in the amount of
$19,309,403 to be disbursed over a total period of 4 years to StemCells, Inc. (Organization ID PR-Y0026A-SF) in support of the above referenced project. This award is made pursuant to the California Stem Cell Research and Cures Act
(Health and Safety Code section 125290.10 et. seq.) and is subject to the Terms and Conditions referenced below. Capitalized terms are defined herein or in the CIRM Loan Administration Policy, (LAP), a copy of which is attached as
Exhibit B to the Loan Agreement between CIRM and StemCells, Inc., dated April 5th, 2013 (“Loan Agreement”), or in the Loan Agreement, as applicable. 
 By accepting this
Loan, the Loan Recipient warrants to CIRM that any funds expended under the award will be used for the purposes set forth in the approved application and this Notice of Loan Award (NLA) and agrees to comply with all applicable CIRM regulations and
standards. 
 To accept this Loan, the Principal Investigator and Authorized Organizational Official must sign and return this NLA to CIRM
within 45 days of the issue date. Payment will be issued only after the signed NLA is received by CIRM. Loan funds will be sent to the organization’s address listed above under Official and Address to Receive Payments
unless an updated address is provided in the box below. If the applicant cannot accept the award, including the legal obligation to perform in accordance with the provisions of this NLA, it should notify CIRM immediately.

 If you have any questions about this award, please contact the CIRM staff referenced on page 5. 

 

			
		 	Updated Address to Receive
Payments:
		 
		 
		 
		 
	Elona Baum, Esq.	 
	General Counsel and Vice President,	 
	Business Development	 
	California Institute for Regenerative Medicine	 

 AWARD ACCEPTANCE: The Principal Investigator and Authorized Organizational Official must sign below and return the entire
NLA to CIRM to accept the Loan award on the terms provided herein and in the Appendices which are attached hereto and incorporated herein. 
  

					
	 	  	 Principal Investigator
	  	
Authorized Organizational Official

	 Name
	  	Alexandra Capela	  	Ann Tsukamoto
	 Signature
	  	/s/ Alexandra Capela	  	/s/ Ann Tsukamoto
	 Date
	  	April 10, 2013	  	April 10, 2013

 SIGN AND RETURN ALL PAGES TO CIRM 
 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

 TERMS AND CONDITIONS OF AWARD 

 

	A.	This award is based on the application submitted to CIRM, and as approved by the Independent Citizens’ Oversight Committee (ICOC) on the above-titled project and
is subject to the terms and conditions incorporated either directly or by reference in the following: 

  

	 	1.	The California Stem Cell Research and Cures Act (Health and Safety Code Section 125290.10 et. seq.) and regulations adopted by the ICOC.

  

	 	2.	The CIRM Loan Administration Policy (Cal. Code Regs., tit. 17, § 100800 et seq.), the CIRM Scientific and Medical Accountability Standards (Cal. Code
Regs., tit. 17, § 100100 et seq.), the CIRM Intellectual Property and Revenue Sharing Requirements for Non-Profit and For-Profit Grantees (Cal. Code Regs., tit. 17, § 100600 et seq.). 

 

	 	3.	The terms and requirements detailed in RFA 10-05: CIRM Disease Team Therapy Development Research Awards. 

 

	 	4.	The Progress Milestones and Go/No Go Milestones set out in Appendix A to this NLA and in the Loan Agreement executed by CIRM and Loan Recipient, attached hereto as
Appendix B. In the event of a conflict between this Notice of Loan Award and the Loan Agreement, the terms of the Loan Agreement will prevail. 

  

	 	5.	Budget detail for the Principal Investigator and the Co-Principal Investigator(s) set out below. 

 

	B.	The CIRM-funded project shall commence no later than January 1, 2014. The Loan Recipient shall notify CIRM at least 30 days in advance of its intended start date
so that CIRM has adequate time to conduct Pre-Funding Administrative Review (PFAR) of the project. During PFAR, the Loan Recipient shall submit an updated budget, personnel listing, timelines, protocol approvals, and any other information and
documents deemed relevant by CIRM. The Loan Recipient shall not receive any disbursement of CIRM funds, and shall not commence the CIRM-funded project, until PFAR has concluded, and CIRM has reviewed and approved all relevant documents.

  

	C.	If the Loan Recipient fails to give notice by December 1, 2013, of its intention to commence the CIRM-funded project, or fails to commence the CIRM-funded project
by January 1, 2014, CIRM may terminate the award. 

  

	D.	In applying for CIRM funding, Loan Recipient represented to CIRM that it possesses certain intellectual property relevant to the CIRM-funded project (prior IP). These
representations were material to CIRM’s funding decision. Accordingly, Loan Recipient shall take all appropriate steps to maintain and preserve its patent rights in such prior IP, and shall not abandon any such rights without prior written
approval of CIRM. 

  

	E.	If CIRM determines, in its sole discretion, that Loan Recipient has not satisfied a Progress Milestone, CIRM may suspend Disbursements until such time as Loan Recipient
satisfies the Progress Milestone. Upon suspending Disbursements, CIRM may convene its progress Evaluation Committee and may seek input from Loan Recipient in order to evaluate the circumstances of the delay, including but not limited to, its cause,
impact and any mitigating factors; provided, however, that CIRM may permanently cease Disbursements if Loan Recipient does not satisfy the Progress Milestone within four (4) months of the date that the Progress Milestone was scheduled to have
been satisfied, or if the delay is not addressed to CIRM’s satisfaction, as determined by CIRM in its sole discretion. 

  

	F.	Subject to the provisions of Section 4.4(c) of the CIRM Loan Agreement, CIRM may suspend or permanently cease Disbursements if CIRM determines, in its sole but
reasonable discretion, that a No Go Milestone has occurred (as defined in the Loan Agreement) or that Loan Recipient has not satisfied a Go/No Go Milestone. 

 

	G.	CIRM has the right to attend as an observer key Food and Drug Administration (FDA) meetings regarding the CIRM-Funded Project, including but not limited to any pre-
pre-IND meeting, pre-IND meeting, clinical milestone meeting, or clinical hold meeting (FDA Meetings). CIRM also has the right to review any data 

 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

	 	
package(s) or other information, including confidential and/or proprietary information, provided by Loan Recipient to the FDA in connection with such FDA Meetings, as well as any FDA Meeting
minutes relating thereto, and to share such information with CIRM’s confidential advisers. To facilitate CIRM’s participation in FDA Meetings, Loan Recipient shall notify CIRM as soon as practicable after it has scheduled an FDA Meeting,
and shall, upon request, provide CIRM a copy of any data package or other information it intends to provide or has provided to the FDA, as well as any FDA Meeting minutes. 

 

	H.	The timing of the distribution of funds pursuant to this award shall be contingent upon the availability of funds in the California Stem Cell Research and Cures Fund in
the State Treasury, as determined by CIRM in its sole discretion. 

 Please check the CIRM website for updated policy documents:
http://www.cirm.ca.gov/cirm-operations/Regulations 
 AWARD DETAIL (U.S. Dollars): 

 

																	
	 	  	Year 1	 	 	Year 2	 	 	Year 3	 	 	Year 4	 
	 Total CIRM Project Costs
	  				 				 				 			
	 CIRM Principal Investigator
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 CIRM Co-Principal Investigator (1)
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 APPROVED BUDGET TOTAL
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Grantee Matching Funds
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 

 PI: Alexandra Capela 
  

																	
	 	  	Year 1	 	 	Year 2	 	 	Year 3	 	 	Year 4	 
	 Personnel Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Travel
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Supplies
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Equipment
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Consultants/Subcontracts
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Total Direct Project Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Facilities Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Indirect Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 APPROVED BUDGET TOTAL
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 

 Co-PI: Frank LaFerla 
  

																	
	 	  	Year 1	 	 	Year 2	 	 	Year 3	 	 	Year 4	 
	 Personnel Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Travel
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Supplies
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Equipment
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Consultants/Subcontracts
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Total Direct Project Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Facilities Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
	 Indirect Costs
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 APPROVED BUDGET TOTAL
	  	 	[****	] 	 	 	[****	] 	 	 	[****	] 	 	 	[****	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 

 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

 SEMI-ANNUAL INSTALLMENTS ON CIRM DISBURSEMENTS 
 Disbursements will be made in semi-annual installments, issued at the beginning of each 6-month period. These periods will be tied to the project start date and payments will be made based on the figures
provided above. The disbursement schedule for Years 2, 3 and 4 assumes that all Go/No-Go and Progress milestones are met. If some milestones are unmet at the end of Year 1, 2, or 3, CIRM may adjust the disbursement schedule for subsequent years,
based on the Project Costs associated with the elements of the milestones that are unmet, after consultation with the Loan Recipient. 

Disbursement Schedule: 
  

									
	 Payment #:
	  	 Type
	  	Schedule Date**	  	Amount	 
	1	  	Pre-Award Financial Due Diligence*	  	4/1/2013	  	 	[****	] 
	2	  	Year 1 Q1Q2 Payment	  	~7/1/2013	  	 	[****	] 
	3	  	Year 1 Q2Q3 Payment	  	~1/1/2014	  	 	[****	] 
	4	  	Year 2 Financial Due Diligence*	  	~7/1/2014	  	 	[****	] 
	5	  	Year 2 Q1Q2 Payment	  	~7/1/2014	  	 	[****	] 
	6	  	Year 2 Q3Q4 Payment	  	~1/1/2015	  	 	[****	] 
	7	  	Year 3 Financial Due Diligence*	  	~7/1/2015	  	 	[****	] 
	8	  	Year 3 Q1Q2 Payment	  	~7/1/2015	  	 	[****	] 
	9	  	Year 3 Q3Q4 Payment	  	~1/1/2016	  	 	[****	] 
	10	  	Year 4 Financial Due Diligence*	  	~7/1/2016	  	 	[****	] 
	11	  	Year 4 Q1Q2 Payment	  	~7/1/2016	  	 	[****	] 
	12	  	Year 4 Q3Q4 Payment	  	~1/1/2017	  	 	[****	] 

  

	*	Amounts specified in section 4.6 (b) of the Loan Agreement will be delivered by CIRM directly to the service provider. 

	**	Assumes a Project Start Date of July 1, 2013. 

 REPORT SCHEDULE 
  

					
	 Report Type
	  	Report Period	  	Due
Date**
	 Quarterly Progress Report
	  	Year 1 Q1	  	10/1/2013
	 Quarterly Cash-on-Hand Report
	  	Year 1 Q1	  	10/15/2013
	 Financial Milestone Review
	  	Year 1Q2	  	12/1/2013
	 Quarterly Progress Report
	  	Year 1 Q2	  	1/1/2014
	 Quarterly Cash-on-Hand Report
	  	Year 1 Q2	  	1/15/2014
	 Quarterly Progress Report
	  	Year 1 Q3	  	4/1/2014
	 Quarterly Cash-on-Hand Report
	  	Year 1 Q3	  	4/15/2014
	 Financial Milestone Review
	  	Year 2	  	6/1/2014
	 Annual Progress Report
	  	Year 1	  	7/1/2014
	 Annual Financial Report
	  	Year 1	  	10/1/2014
	 Quarterly Progress Report
	  	Year 2 Q1	  	10/1/2014
	 Quarterly Cash-on-Hand Report
	  	Year 2 Q1	  	10/15/2014
	 Financial Milestone Review
	  	Year 2Q2	  	12/1/2014
	 Quarterly Progress Report
	  	Year 2 Q2	  	1/1/2015
	 Quarterly Cash-on-Hand Report
	  	Year 2 Q2	  	1/15/2015
	 Quarterly Progress Report
	  	Year 2 Q3	  	4/1/2015
	 Quarterly Cash-on-Hand Report
	  	Year 2 Q3	  	4/15/2015
	 Financial Milestone Review
	  	Year 3	  	6/1/2015
	 Annual Progress Report
	  	Year 2	  	7/1/2015
	 Annual Financial Report
	  	Year 2	  	10/1/2015
	 Quarterly Progress Report
	  	Year 3 Q1	  	10/1/2015
	 Quarterly Cash-on-Hand Report
	  	Year 3 Q1	  	10/15/2015
	 Financial Milestone Review
	  	Year 3 Q2	  	12/1/2015
	 Quarterly Progress Report
	  	Year 3 Q2	  	1/1/2016
	 Quarterly Cash-on-Hand Report
	  	Year 3 Q2	  	1/15/2016
	 Quarterly Progress Report
	  	Year 3 Q3	  	4/1/2016
	 Quarterly Cash-on-Hand Report
	  	Year 3 Q3	  	4/15/2016

 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

					
	 Financial Milestone Review
	  	Year 4	  	6/1/2016
	 Annual Progress Report
	  	Year 3	  	7/1/2016
	 Annual Financial Report
	  	Year 3	  	10/1/2016
	 Quarterly Progress Report
	  	Year 4 Q1	  	10/1/2016
	 Quarterly Cash-on-Hand Report
	  	Year 4 Q1	  	10/15/2016
	 Financial Milestone Review
	  	Year 4Q2	  	12/1/2016
	 Quarterly Progress Report
	  	Year 4 Q2	  	1/1/2017
	 Quarterly Cash-on-Hand Report
	  	Year 4 Q2	  	1/15/2017
	 Quarterly Progress Report
	  	Year 4 Q3	  	4/1/2017
	 Quarterly Cash-on-Hand Report
	  	Year 4 Q3	  	4/15/2017
	 Annual Progress Report
	  	Year 4	  	7/1/2017
	 Annual Financial Report
	  	Year 4	  	10/1/2017

  

	**	Assumes a Project Start Date of July 1, 2013. 

 For an explanation of reporting requirements, please refer to the Loan Administration Policy (Rev May 2012; http://www.cirm.ca.gov/files/transcripts/pdf/2012/09-05-12.pdf) as well as the
“Reporting Requirements for Disease Team Research Awards” document provided separately. 
 CIRM CONTACTS: 

Gabriel Thompson, Deputy Grants Management Officer 
 Phone: 415-608-####         Email: xxxxxxx@cirm.ca.gov         Fax: (415) 396-#### 

Catherine Priest, Science Officer 
 Phone:
415-396-####         Email: xxxxx@cirm.ca.gov             Fax: (415) 396-#### 
 CIRM Mailing Address: 
 California Institute for Regenerative Medicine 

Attn: Grants Management Office 
 210 King Street

 San Francisco, CA 94107 
 The CIRM
home page is at http://www.cirm.ca.gov 
 [****] Certain information has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions. 

  

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

 APPENDICES 

 

			
	 Appendix A
	  	Research Milestones
	 Appendix B
	  	Loan Agreement

  

	
	CIRM USE ONLY: 6445-601-6047001/H&S Code 125291.20 Statutes
2004

 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

 APPENDIX A – CIRM RFA-10-01: (RFA 10-05) Disease Team Therapy Development Awards

 California Institute for Regenerative Medicine 

 

							
	 Grant Number:
 Grantee
Name:
	  	 DR2A-05416
 StemCells,
Inc.
	  	Budget Period:	  	Annual beginning on the
Project Start Date
	Grantee ID:	  	PR-Y0027A-LA	  	Project Period Start:	  	On or before 1/1/2014
	 Principal Investigator:

Co-Principal Investigator (s):
 Project
Title:
	  	 Alexandra Capela
 Frank
LaFerla
	  	Project Period End:	  	6/30/2017, assuming a
7/1/2013 Project Start Date

 Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy 

Milestone achievement is an important indicator of progress and is a major factor in review of progress reports. Insufficient progress through milestones
may result in loss of further funding. The milestones summarized below replace the milestones proposed in the original Application. These milestones will be used as a basis for review in the progress reports and progress Evaluation Meetings unless
further modified with Prior Approval from CIRM. 
 RESEARCH MILESTONES 
 (Assumes a Project Start Date of July 1, 2013) 
 Year 1 = July 2013-June 2014 

Year 2 = July 2014-June 2015 
 Year 3 = July
2015-June 2016 
 Year 4 = July 2016-June 2017 
 Year 1 Milestones 
  

													
	 	  	 Milestone
	  	Target
completion
date	 	  	Progress
or Go/No
Go	 	  	 Comments, &

Potential Risks
 to Timeline

	 Pharm/tox
	  	[****]	  	 	Y1 Q3	  	  	 	Go / No Go	  	  	[****]

 Year 2 Milestones 
  

													
	 	  	 Milestone
	  	Target
completion
date	 	  	Progress or
Go/No Go	 	  	 Comments &

Potential Risks
 to Timeline

	 Pharm/tox
	  	[****]	  	 	Y2 Q3	  	  	 	Go / No Go	  	  	[****]
					
		  	[****]	  	 	Y2 Q3	  	  	 	Go / No Go	  	  	[****]
	 CMC
	  	[****]	  	 	Y2Q2	  	  	 	Go / No Go	  	  	[****]
	 Clinical/
Regulatory
	  	[****]	  	 	Y2 Q4	  	  	 	Go / No Go	  	  	[****]

 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  

			
	NOTICE OF LOAN AWARD        	 	        DR2A-05416

  

 Year 3 Milestones 

 

													
	 	  	 Milestone
	  	Target
completion
date	 	  	Progress
or Go/No
Go	 	  	 Comments &

Potential Risks
 to Timeline

	 Pharm/tox
	  	[****]	  	 	Y4 Q2	  	  	 	Go / No Go	  	  	 Failure to initiate IND-enabling efficacy studies could delay completion and potential IND filing.

 
 Failure to establish behavior and histopathology efficacy would be a No Go
event.

	 Clinical/
Regulatory
	  	[****]	  	 	Y4 Q3	  	  	 	Go / No Go	  	  	 Failure to initiate pivotal GLP safety study could delay completion and potential IND.

 
 Failure to establish safety would be a No Go event.

 Year 4 Milestones 
  

													
	 	  	 Milestone
	  	Target
completion
date	 	  	Progress
or Go/No
Go	 	  	 Comments &

Potential Risks
 to Timeline

	 Clinical/
Regulatory
	  	8. File IND	  	 	Y4 Q4	  	  	 	Progress	  	  	

 [****] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions.EX-10.1

 Exhibit 10.1 
 ENDURANCE INTERNATIONAL GROUP HOLDINGS, INC. 
 2013 STOCK INCENTIVE PLAN

 1. Purpose 
 The purpose of this 2013 Stock Incentive Plan (the “Plan”) of Endurance International Group Holdings, Inc., a Delaware corporation (the
“Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by
providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires,
the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations
thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of
the Company (the “Board”). 
 2. Eligibility 

All of the Company’s employees, officers and directors, as well as consultants and advisors to the Company (as such
terms are defined and interpreted for purposes of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), or any successor form) are eligible to be granted Awards under the Plan. Each person who is
granted an Award under the Plan is deemed a “Participant.” “Award” means Options (as defined in Section 5), SARs (as defined in Section 6), Restricted Stock (as defined in Section 7),
Restricted Stock Units (as defined in Section 7) and Other Stock-Based Awards (as defined in Section 8).  
 3.
Administration and Delegation 
 (a) Administration by Board of Directors. The Plan will be administered by the
Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and
any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient and it shall be the sole and
final judge of such expediency. All decisions by the Board shall be made in the Board’s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. 

(b) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under
the Plan to one or more committees or subcommittees of the Board (a “Committee”). All references in the Plan to the “Board” shall mean the Board or a Committee of the Board or the officers referred to
in Section 3(c) to the extent that the Board’s powers or authority under the Plan have been delegated to such Committee or officers. 

 (c) Delegation to Officers. To the extent permitted by applicable law, the Board may
delegate to one or more officers of the Company the power to grant Options and other Awards that constitute rights under Delaware law (subject to any limitations under the Plan) to employees or officers of the Company and to exercise such other
powers under the Plan as the Board may determine, provided that the Board shall fix the terms of such Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the exercise price
will be determined) and the maximum number of shares subject to such Awards that the officers may grant; provided further, however, that no officer shall be authorized to grant such Awards to any “executive officer” of the Company
(as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) or to any “officer” of the Company (as defined by Rule 16a-1 under the Exchange Act). The Board may not delegate
authority under this Section 3(c) to grant Restricted Stock, unless Delaware law then permits such delegation. 
 4. Stock Available for
Awards 
 (a) Number of Shares; Share Counting. 

(1) Authorized Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan (any or all of which
Awards may be in the form of Incentive Stock Options, as defined in Section 5(b)) for 18,000,000 shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”). Shares issued under the Plan may
consist in whole or in part of authorized but unissued shares or treasury shares. 
 (2) Share Counting. For purposes of
counting the number of shares available for the grant of Awards under the Plan: 
 (A) all shares of Common Stock covered by
SARs shall be counted against the number of shares available for the grant of Awards under the Plan; provided, however, that (i) SARs that may be settled only in cash shall not be so counted and (ii) if the Company grants an SAR in
tandem with an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a “Tandem SAR”), only the shares covered by the Option, and not the shares covered by the Tandem SAR,
shall be so counted, and the expiration of one in connection with the other’s exercise will not restore shares to the Plan; 
 (B) if any Award (i) expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock
subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii) results in any Common Stock not being issued (including as a result of an SAR that was settleable either
in cash or in stock actually being settled in cash), the unused Common Stock covered by such Award shall again be available for the grant of Awards; provided, however, that (1) in the case of Incentive Stock Options, the foregoing shall
be subject to any limitations under the Code, (2) in the case of the exercise of an SAR, the number of shares counted against the shares available under the Plan and against the sublimits listed in the first clause of this Section 4(a)(2)
shall be the full number of shares subject to the SAR multiplied by the percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3) the shares covered by a Tandem SAR shall
not again become available for grant upon the expiration or termination of such Tandem SAR; and 

  
 -2-

 (C) shares of Common Stock delivered (either by actual delivery, attestation, or net
exercise) to the Company by a Participant to (i) purchase shares of Common Stock upon the exercise of an Award or (ii) satisfy tax withholding obligations (including shares retained from the Award creating the tax obligation) shall be
added back to the number of shares available for the future grant of Awards. 
 (b) Substitute Awards. In connection with
a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an
affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit
set forth in Section 4(a)(1) or any sublimit contained in the Plan, except as may be required by reason of Section 422 and related provisions of the Code. 
 5. Stock Options 
 (a) General. The Board may grant options to
purchase Common Stock (each, an “Option”) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of
each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. 
 (b) Incentive Stock Options. An Option that the Board intends to be an “incentive stock option” as defined in Section 422 of the Code (an “Incentive Stock
Option”) shall only be granted to employees of Endurance International Group Holdings, Inc., any of Endurance International Group Holdings, Inc.’s present or future parent or subsidiary corporations as defined in Sections 424(e) or
(f) of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code. An
Option that is not intended to be an Incentive Stock Option shall be designated a “Nonstatutory Stock Option.” The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that
is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. 
 (c) Exercise Price. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement. The exercise price shall be not less
than 100% of the fair market value per share of Common Stock as determined by (or in a manner approved by) the Board (“Fair Market Value”) on the date the Option is granted; provided that if
the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date.  

  
 -3-

 (d) Duration of Options. Each Option shall be exercisable at such times and subject
to such terms and conditions as the Board may specify in the applicable option agreement; provided, however, that no Option will be granted with a term in excess of 10 years. 

(e) Exercise of Options. Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be
electronic) approved by the Company, together with payment in full (in the manner specified in Section 5(f)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be
delivered by the Company as soon as practicable following exercise. 
 (f) Payment Upon Exercise. Common Stock purchased
upon the exercise of an Option granted under the Plan shall be paid for as follows: 
 (1) in cash or by check, payable to the
order of the Company; 
 (2) except as may otherwise be provided in the applicable Option agreement or approved by the Board, in
its sole discretion, by (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery
by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

(3) to the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by delivery (either
by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if acquired
directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting
or other similar requirements; 
 (4) to the extent provided for in the applicable Nonstatutory Stock Option agreement or
approved by the Board in its sole discretion, by delivery of a notice of “net exercise” to the Company, as a result of which the Participant would receive (i) the number of shares underlying the portion of the Option being exercised,
less (ii) such number of shares as is equal to (A) the aggregate exercise price for the portion of the Option being exercised divided by (B) the Fair Market Value on the date of exercise; 

(5) to the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole
discretion, by payment of such other lawful consideration as the Board may determine; or 
 (6) by any combination of the above
permitted forms of payment. 
 (g) Limitation on Repricing. Unless such action is approved by the Company’s
stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such
outstanding Option, (2) cancel any 

  
 -4-

 
outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section 4(c)) covering the same
or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option, (3) cancel in exchange for a cash payment any outstanding Option with an
exercise price per share above the then-current Fair Market Value, or (4) take any other action under the Plan that constitutes a “repricing” within the meaning of the rules of the NASDAQ Stock Market. 

6. Stock Appreciation Rights 
 (a) General. The Board may grant Awards consisting of stock appreciation rights (“SARs”) entitling the holder, upon exercise, to receive an amount of Common Stock or cash or
a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established pursuant to
Section 6(b). The date as of which such appreciation is determined shall be the exercise date. 
 (b) Measurement
Price. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; provided that if
the Board approves the grant of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair Market Value on such future date. 
 (c) Duration of SARs. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; provided, however, that
no SAR will be granted with a term in excess of 10 years. 
 (d) Exercise of SARs. SARs may be exercised by delivery to
the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board. 
 (e) Limitation on Repricing. Unless such action is approved by the Company’s stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding SAR
granted under the Plan to provide a measurement price per share that is lower than the then-current measurement price per share of such outstanding SAR, (2) cancel any outstanding stock appreciation right (whether or not granted under the Plan)
and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section 4(c)) covering the same or a different number of shares of Common Stock and having a measurement price per share lower than the
then-current measurement price per share of the cancelled stock appreciation right, (3) cancel in exchange for a cash payment any outstanding SAR with a measurement price per share above the then-current Fair Market Value, or (4) take any
other action under the Plan that constitutes a “repricing” within the meaning of the rules of the NASDAQ Stock Market. 

  
 -5-

 7. Restricted Stock; Restricted Stock Units 

(a) General. The Board may grant Awards entitling recipients to acquire shares of Common Stock
(“Restricted Stock”), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no
cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant
Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at the time such Award vests (“Restricted Stock Units”) (Restricted Stock and Restricted Stock Units are each referred to herein as a
“Restricted Stock Award”). 
 (b) Terms and Conditions for All Restricted Stock
Awards. The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. 

(c) Additional Provisions Relating to Restricted Stock. 
 (1) Dividends. Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash, stock or property) declared and paid by the Company with respect to shares of
Restricted Stock (“Accrued Dividends”) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. Each payment of Accrued
Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and
the forfeitability provisions applicable to the underlying shares of Restricted Stock. 
 (2) Stock Certificates. The
Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power
endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the
Participant has died, to his or her Designated Beneficiary. “Designated Beneficiary” means (i) the beneficiary designated, in a manner determined by the Board, by a Participant to receive
amounts due or exercise rights of the Participant in the event of the Participant’s death or (ii) in the absence of an effective designation by a Participant, the Participant’s estate. 

(d) Additional Provisions Relating to Restricted Stock Units. 

(1) Settlement. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted
Stock Unit, the Participant shall be entitled to receive from the Company one share of Common Stock or (if so provided in the applicable Award agreement) an amount of cash equal to the Fair Market Value of one share of Common Stock. The Board may,
in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section 409A of the Code. 

(2) Voting Rights. A Participant shall have no voting rights with respect to any Restricted Stock Units. 

  
 -6-

 (3) Dividend Equivalents. The Award agreement for Restricted Stock Units may provide
Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (“Dividend Equivalents”). Dividend Equivalents may be
paid currently or credited to an account for the Participant, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid,
in each case to the extent provided in the Award agreement. 
 8. Other Stock-Based Awards 

(a) General. Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by
reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants
(“Other Stock-Based-Awards”). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards
granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine.  

(b) Terms and Conditions. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other
Stock-Based Award, including any purchase price applicable thereto. 
 9. Adjustments for Changes in Common Stock and Certain Other
Events 
 (a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend,
recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the number
and class of securities available under the Plan, (ii) the share counting rules and sublimit set forth in Sections 4(a) and 4(b), (iii) the number and class of securities and exercise price per share of each outstanding Option,
(iv) the share and per-share provisions and the measurement price of each outstanding SAR, (v) the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (vi) the share
and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board.
Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the
date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the
distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock
dividend. 

  
 -7-

 (b) Reorganization Events. 

(1) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company
with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the
Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 
 (2) Consequences of a Reorganization Event on Awards Other than Restricted Stock. 
 (A) In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock on such terms
as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant): (i) provide that such Awards shall be assumed, or substantially
equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that all of the Participant’s unexercised Awards will terminate immediately
prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that outstanding Awards shall become
exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of Common
Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “Acquisition Price”), make or provide for a cash payment to Participants with respect to each Award held
by a Participant equal to (A) the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by
(B) the excess, if any, of (I) the Acquisition Price over (II) the exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v) provide that, in
connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and
(vi) any combination of the foregoing. In taking any of the actions permitted under this Section 9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type,
identically. 
 (B) Notwithstanding the terms of Section 9(b)(2)(A), in the case of outstanding Restricted Stock Units
that are subject to Section 409A of the Code: (i) if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a “change in control event” within the meaning of Treasury
Regulation Section 1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a “change in control event”, then no assumption or substitution shall be permitted pursuant to Section 9(b)(2)(A)(i) and the Restricted Stock
Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii) the Board may only undertake the actions set forth in clauses (iii), (iv) or (v) of Section 9(b)(2)(A) if the
Reorganization Event constitutes a “change in control event” as defined under Treasury Regulation Section 1.409A-3(i)(5)(i) and such action is 

  
 -8-

 
permitted or required by Section 409A of the Code; if the Reorganization Event is not a “change in control event” as so defined or such action is not permitted or required by
Section 409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i) of Section 9(b)(2)(A), then the unvested Restricted Stock Units shall terminate
immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor. 
 (C) For purposes
of Section 9(b)(2)(A)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for
each share of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common
Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding
shares of Common Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the
consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or
an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a
result of the Reorganization Event. 
 (3) Consequences of a Reorganization Event on Restricted Stock. Upon the
occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company’s successor and
shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied
to such Restricted Stock; provided, however, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a
Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument
evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied. 

10. General Provisions Applicable to Awards 
 (a) Transferability of Awards. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law,
except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant;
provided, however, that 

  
 -9-

 
the Board may permit or provide in an Award for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity
established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Common Stock subject to such Award to such
proposed transferee; provided further, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written
instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references
to authorized transferees. For the avoidance of doubt, nothing contained in this Section 10(a) shall be deemed to restrict a transfer to the Company. 
 (b) Documentation. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set
forth in the Plan. 
 (c) Board Discretion. Except as otherwise provided by the Plan, each Award may be made alone or in
addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. 
 (d) Termination of Status. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in
the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the
Award. 
 (e) Withholding. The Participant must satisfy all applicable federal, state, and local or other income
and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to satisfy the withholding obligations through additional
withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the
withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price, unless the
Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common
Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; provided, however, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy
such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental
taxable income). Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. 

  
 -10-

 (f) Amendment of Award. Except as provided in Sections 5(g) and 6(e) with respect to
repricings or Section 11(d) with respect to actions requiring stockholder approval, the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different
type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant’s consent to such action shall be required unless (i) the Board determines that the action, taking
into account any related action, does not materially and adversely affect the Participant’s rights under the Plan or (ii) the change is permitted under Section 9. 

(g) Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan
or to remove restrictions from shares previously issued or delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company’s counsel, all
other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii) the
Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

(h) Acceleration. The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free
of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. 
 11. Miscellaneous

 (a) No Right To Employment or Other Status. No person shall have any claim or right to be granted an Award by virtue of
the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or
otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. 
 (b) No Rights As Stockholder. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common
Stock to be distributed with respect to an Award until becoming the record holder of such shares. 
 (c) Effective Date and
Term of Plan. The Plan shall become effective on the date the Plan is approved by the Company’s stockholders (the “Effective Date”). No Awards shall be granted under the Plan after the expiration of 10 years from the
Effective Date, but Awards previously granted may extend beyond that date. 
 (d) Amendment of Plan. The Board may amend,
suspend or terminate the Plan or any portion thereof at any time provided that (i) to the extent required by Section 162(m), no Award granted to a Participant that is intended to comply with Section 162(m) after the date of such
amendment shall become exercisable, realizable or vested, as applicable to such Award, unless and until the Company’s stockholders approve such amendment in the manner required by 

  
 -11-

 
Section 162(m); and (ii) no amendment that would require stockholder approval under the rules of the NASDAQ Stock Market may be made effective unless and until the Company’s
stockholders approve such amendment;. In addition, if at any time the approval of the Company’s stockholders is required as to any other modification or amendment under Section 422 of the Code or any successor provision with respect to
Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section 11(d) shall apply to, and be
binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of
Participants under the Plan. No Award shall be made that is conditioned upon stockholder approval of any amendment to the Plan unless the Award provides that (i) it will terminate or be forfeited if stockholder approval of such amendment is not
obtained within no more than 12 months from the date of grant and (2) it may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval. 

(e) Authorization of Sub-Plans (including for Grants to non-U.S. Employees). The Board may from time to time establish one or more
sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i) such limitations on the
Board’s discretion under the Plan as the Board deems necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by
the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction
which is not the subject of such supplement. 
 (f) Compliance with Section 409A of the Code. Except as provided in
individual Award agreements initially or by amendment, if and to the extent (i) any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with his or her employment termination
constitutes “nonqualified deferred compensation” within the meaning of Section 409A of the Code and (ii) the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, in each case as determined
by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that
is six months plus one day after the date of “separation from service” (as determined under Section 409A of the Code) (the “New Payment Date”), except as Section 409A of the Code may then permit. The
aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any
remaining payments will be paid on their original schedule. 
 The Company makes no representations or warranty and shall have no liability to
the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not to satisfy the
conditions of that section. 

  
 -12-

 (g) Limitations on Liability. Notwithstanding any other provisions of the Plan, no
individual acting as a director, officer, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the
Plan, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee or agent of the Company. The Company will indemnify
and hold harmless each director, officer, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys’
fees) or liability (including any sum paid in settlement of a claim with the Board’s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person’s own fraud or bad faith. 

(h) Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance
with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware. 

  
 -13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]